BILL OF SALE (Amended)Bill of Sale • November 14th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
THIS BILL OF SALE (“Bill of Sale”), is made effective as of the 16th day of March, 2018 by and between HEMISPHERX BIOPHARMA, INC., a Delaware corporation whose address is 860 North Orange Avenue, Suite B, Orlando, Florida 32801-5205 (the “Seller”) and 783 JERSEY AVENUE LLC, a New Jersey limited liability company, whose address is PO Box 230, Oceanport, New Jersey 07757 (the “Purchaser”).
FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENTPurchase and Sale Agreement • November 14th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New Jersey
THIS FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (“Amendment”) is made as of this __ day of March, 2018, by and between HEMISPHERX BIOPHARMA, INC., a Delaware corporation (the “Seller”), and 783 JERSEY AVENUE, LLC, a New Jersey limited liability company, successor-by-assignment to Capital Realty & Investment Co., LLC (the “Purchaser”).
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • November 14th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (“Agreement”), made as of October 9, 2018 (the “Effective Date”), by and between ROSWELL PARK CANCER INSTITUTE CORPORATION (“Institution”), a New York State public benefit corporation, with its principal office located at Elm and Carlton Streets, Buffalo, NY 14263 and employer of Pawel Kalinski, MD (“Principal Investigator”), and HEMISPHERX BIOPHARMA, INC. a corporation organized under the laws of Delaware, having an office at 2117 SW Highway 484, Ocala, FL 34473 (hereinafter “Hemispherx”).
